On June 27, 2025, Deputy High Court Judge Jonathan Wong of the High Court of Hong Kong ruled in favor of Sinovac Biotech, Ltd. (Sinovac), 1Globe Capital LLC (1Globe), and OrbiMed Partners Master Fund Limited (OrbiMed), refusing Prime Success, L.P.’s ex parte application for urgent injunctive relief in aid of arbitration. The court also declined an application by Vivo Capital, LLC and its affiliates to join the ex parte application.

On June 24, 2025, Prime Success delivered an ex parte application seeking an urgent “interim-interim” injunction prohibiting Sinovac from prosecuting a currently pending Antiguan court proceeding, essentially the same relief sought by Prime Success in a recent New York petition that was denied by the U.S. District Court for the Southern District of New York on June 20, 2025. For more information about the prior New York action, please see our firm’s previous client highlight. On June 26, 2025, Vivo Capital and its affiliates also sought to join the application as additional plaintiffs. The application was heard and decided on June 27, 2025. 

The Hong Kong court’s refusal of urgent injunctive relief marked another success by Wilson Sonsini in opposing a series of legal actions taken by Prime Success and Vivo Capital against Sinovac. In reaching his decision, Judge Wong criticized Prime Success for failing to make full and frank disclosure in the ex parte application and noted that its claimed urgency was self-induced. To further underscore the victory, Judge Wong also ordered that legal costs incurred in opposing the application be compensated by Prime Success to Sinovac, 1Globe, and OrbiMed.

The Wilson Sonsini team was led by partners Weiheng Chen and Matthew Reed and China partner Draco Ng.